S-1: BioAffinity Technologies Faces Delisting Amid Share Resale Plan

BioAffinity Technologies files S-1 to register 12.6 million shares for resale by investors, following recent private placements and facing potential Nasdaq delisting due to bid price and equity deficiencies.

Summary

• BioAffinity Technologies, Inc. has filed an S-1 registration statement for the resale of up to 12,611,253 shares of common stock by existing Selling Stockholders.
• The company will not receive any proceeds from the sale of these shares by the Selling Stockholders, but will receive proceeds from the cash exercise of Common Warrants and conversion of Series B Preferred Stock.
• Recent financing activities include an August 14, 2025 private placement generating approximately $1.2 million in gross proceeds through the issuance of Series B Convertible Preferred Stock and Private Warrants.
• An additional warrant inducement transaction on August 14, 2025, generated approximately $253,000 in gross proceeds from the cash exercise of 1,100,000 existing warrants at a reduced price of $0.23 per share, in exchange for new Inducement Warrants.
• The company is currently non-compliant with Nasdaq's minimum bid price ($1.00) and minimum stockholders' equity ($2,500,000) requirements, with stockholders' equity reported at $1,439,404 as of March 31, 2025.
• An appeal against delisting from the Nasdaq Capital Market has been filed, with a hearing scheduled for September 11, 2025.
• The company's independent registered public accounting firm has included an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern in their report dated March 31, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the severe financial risks, including the going concern warning and imminent Nasdaq delisting threat. While recent capital was raised, it appears insufficient to fully address the underlying issues, and the significant potential for dilution further weighs on investor confidence.

Positives

• Successfully completed recent private placements and warrant inducement transactions, raising approximately $1.453 million in gross proceeds for the company.
• Continues to advance development of its noninvasive diagnostic platform, CyPath Lung, for early-stage lung cancer detection, and companion diagnostics for COPD and asthma.
• Engaged in research and development for novel cancer therapeutic approaches, including a topical treatment for squamous cell skin cancer, through its subsidiary OncoSelect Therapeutics, LLC.

Negatives

• The company faces a significant risk of delisting from the Nasdaq Capital Market due to non-compliance with both the $1.00 minimum bid price and the $2,500,000 minimum stockholders' equity requirements.
• The independent auditor's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• The company has a limited operating history and is unable to precisely estimate when it will generate significant profit from its laboratory subsidiary, PPLS.
• Significant potential for dilution exists from the conversion of Series B Preferred Stock, exercise of various warrants (totaling 43,410,568 shares at a weighted average exercise price of $0.96), and stock options (271,987 shares at $7.05).
• The company does not expect to pay dividends in the foreseeable future, and its Common Stock market price ($0.2522 on August 26, 2025) is below the exercise price of many outstanding warrants.

Risks

• Reliance on ability to obtain additional sources of capital and financing to fund operations and continue as a going concern.
• Difficulties in evaluating the business and future prospects due to limited operating history.
• Delays or difficulties in patient enrollment for clinical trials could impede regulatory approvals.
• Clinical trials are expensive, time-consuming, and may not be successful, potentially rendering diagnostic tests or therapeutic product candidates unsafe or ineffective.
• Dependence on the laboratory subsidiary, PPLS, to offer and perform CyPath Lung, with risks related to its operations, including maintaining equipment, accreditation, and courier services.
• Substantial competition in the biotechnology and pharmaceutical industries, and a rapidly changing market for proposed tests and products.
• Potential for substantial costs from product liability lawsuits and failure to comply with privacy, security, and healthcare laws and regulations.
• Inability to obtain adequate reimbursement for diagnostic tests may impact revenues.
• Challenges in protecting intellectual property rights, including potential infringement claims and the need for third-party licenses.
• Failure to comply with laws pertaining to laboratory developed tests (LDTs) or in vitro devices (IVDs) could adversely affect the business.
• Resales of Common Stock by existing stockholders could cause the market price to fall and result in substantial dilution.
• The Nasdaq Capital Market may delist the Common Stock if ongoing listing standards are not met, leading to reduced liquidity and increased price volatility.
• Management will have broad discretion over the use of net proceeds from warrant exercises and Series B conversions, which may not yield favorable returns.

Future Outlook

The company intends to use the net proceeds from the conversion of Series B Preferred Stock and/or cash exercise of Common Warrants for general corporate purposes, including operating expenses, research and development (clinical and pre-clinical testing), working capital, future acquisitions, and general capital expenditures. Management retains broad discretion over these allocations. The company also plans to seek strategic partners to develop its therapeutic discoveries for broad-spectrum cancer treatments.

Management Comments

• Management believes the third-party sources for industry and market data are reliable as of their respective dates.
• Management intends the forward-looking statements to be covered by the safe harbor provisions of federal securities laws.
• Management will have broad discretion as to the use of net proceeds from warrant exercises and Series B conversions.

Industry Context

The company operates in the biotechnology and diagnostics industry, focusing on noninvasive detection of early-stage lung cancer, a significant global health challenge as lung cancer is the leading cause of cancer-related deaths worldwide. Its use of flow cytometry and machine learning (AI) aligns with broader industry trends towards advanced, data-driven diagnostic tools. The development of companion diagnostics for COPD and asthma also positions it within the growing personalized medicine and targeted therapy segments. The therapeutic discoveries for squamous cell skin cancer indicate a diversification into oncology treatments, a highly competitive but potentially lucrative area.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face significant risk of delisting, which could severely impact liquidity and stock value. Potential for substantial dilution from future warrant exercises and conversions. The going concern warning indicates high investment risk.
• **Employees**: The company's financial instability and going concern warning could create uncertainty regarding job security and future operations.
• **Customers**: Continued operation of PPLS and development of diagnostic tests are crucial for customers relying on CyPath Lung and future products. Delisting or financial distress could impact service continuity.
• **Creditors**: The going concern warning and need for additional capital suggest increased risk for existing and potential creditors.
• **Warrant Holders**: While some warrants were exercised, many remain outstanding with exercise prices above the current market price, and their value is highly dependent on the company's ability to regain Nasdaq compliance and improve its financial position.

Next Steps

• Attend the Nasdaq hearing on September 11, 2025, to present plans for regaining compliance with listing standards.
• Seek stockholder approval for the issuance of shares upon exercise of the Inducement Warrants and Private Warrants.
• Continue research and development for diagnostic tests and therapeutic product candidates.
• Seek strategic partners for the development of therapeutic discoveries.

Key Dates

Recommendation

The company faces immediate and severe threats to its existence as a publicly traded entity, including a Nasdaq delisting notice and an auditor's going concern warning. While recent capital was raised, it appears insufficient to resolve these fundamental issues. The significant potential for dilution, coupled with a stock price far below listing requirements and many warrant exercise prices, indicates a highly speculative and distressed investment. The lack of clear profitability and the high operational risks associated with clinical trials and market acceptance further compound the negative outlook, making the stock a strong sell for any seasoned investor or institution.

Keywords

bioAffinity Technologies, BIAF, lung cancer diagnostics, CyPath Lung, AI in diagnostics, biotechnology, SEC filing, S-1, Nasdaq delisting, private placement, warrants, preferred stock, capital raise, going concern, medical technology, corporate governance